

Surgery vs imiquimod for nodular and superficial basal cell carcinoma (SINS)

Investigators: *Fiona Bath-Hextall, Hywel Williams, William Perkins², Jan Bong², Irshad Zaki³, Graham Colver¹, Paul Miller¹, Sarah Armstrong¹, Graeme Perks², Mara Ozolins¹* Clinical Research Nurses: *Joanne Llewellyn¹, Beryl Cunningham³, Sam Annasamy⁴*

¹Departments of Dermatology and Trent RDSU, University of Nottingham, ²Department of Dermatology, QMC, Nottingham, ³Department of Dermatology, Solihull Hospital, ⁴Department of Dermatology, Chesterfield Royal Hospital,.

Data monitoring committee: Nick Telfer (Hope Hospital, Manchester), Stephen Walters (School of Health Related Research, Sheffield), Carol Jagger (Leicester TIHSR).

This is a randomised controlled trial of excisional surgery v's imiquimod 5% cream (Aldara) for nodular and superficial basal cell carcinoma, funded by Cancer Research UK. The study aims to assess cure rates for tumours at low risk sites, cost-effectiveness and cosmetic result. Recurrence at intervals up to five years will also be assessed, the primary assessment point being three years. Genetic markers are also being investigated.

Basal Cell Carcinoma

©Dermatlas; <http://www.dermatlas.org>

The study was originally conducted in three centres: Queen's Medical Centre, Nottingham; Solihull Hospital, Birmingham; and Chesterfield Royal Hospital. To improve the recruitment rate, nine additional centres joined: King's Mill Hospital, Sutton-in-Ashfield; Dorset County Hospital, Dorchester; Inverclyde Royal Hospital, Glasgow; Victoria Infirmary and Southern General Hospital, South Glasgow; Lincoln County and Boston Pilgrim Hospitals, Lincoln; Monklands, Hairmyres and Wishaw Hospitals in Lanarkshire; St.Barts and The London; Broadgreen Hospital, Liverpool; and Birmingham City Hospital.

The study reached its revised recruitment target of 500 patients in February of 2007. The group received an extension with extra funding from Cancer Research UK to complete the three year follow-ups (last visit due March 2010) and also to capture five year outcomes from patient notes. Much of the last year has been spent on data entry and cleaning. Initial analysis of the conjoint data has been performed, which will hopefully be published later this year.

Start date: 16th September 2002

End date: 31st August 2012

Funded by: Cancer Research UK (imiquimod and funding for genetic markers addendum provided by 3M) + small R&D grant (2002-2007).

Publications arising from this study:

None to date